This morning, in a world-first move, Norwegian regulators approved national reimbursement for the off-label use of generic ketamine for treatment-resistant depression. Last month, we covered the publication of a health technology assessment (HTA) of intravenous (IV) ketamine for treatment-resistant depression (TRD). (See Norway’s Health System Considers Funding Off-Label Ketamine for Treatment…
